Patents by Inventor Chengde Wu

Chengde Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10513514
    Abstract: One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: December 24, 2019
    Assignee: SHENZHEN SALUBRIS PHARM CO LTD.
    Inventors: Chengde Wu, Jie Yan, Wenjie Xu, Tao Yu, Ning Li, Shuhui Chen
  • Publication number: 20190375728
    Abstract: The present disclosure relates to a compound as shown in formula (II), a tautomer or a pharmaceutically acceptable salt thereof, and disclosed is the use thereof in preparing a drug for treating an ASK1-associated disease.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 12, 2019
    Inventors: Chengde Wu, Tao Yu, Ning Li, Shuhui Chen
  • Patent number: 10479789
    Abstract: Disclosed in the present invention are a crystalline Form of pyrido[1,2-a]pyrimidone analog, a preparation method therefor and an intermediate thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: November 19, 2019
    Assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Tao Yu, Ning Li, Lingwei Kong, Peipei Jiang, Yong Wang, Zhemin Rong, Changjun Wang, Feng Guo, Zongbin Li, Zheng Wang, Jiahu Wu, Chengde Wu
  • Patent number: 10328054
    Abstract: Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: June 25, 2019
    Assignee: Hua Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Yuejiao Duan, Jin She, Chengde Wu
  • Patent number: 10294236
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: May 21, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
    Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
  • Publication number: 20180319799
    Abstract: Disclosed in the present invention are a crystalline Form of pyrido[1,2-a]pyrimidone analog, a preparation method therefor and an intermediate thereof,
    Type: Application
    Filed: December 16, 2016
    Publication date: November 8, 2018
    Inventors: Tao Yu, Ning Li, Lingwei Kong, Peipei Jiang, Yong Wang, Zhemin Rong, Changjun Wang, Feng Guo, Zongbin Li, Zheng Wang, Jiahu Wu, Chengde Wu
  • Publication number: 20180318254
    Abstract: Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment or prevention of mGluR5 mediated disorders, such as acute and/or chronic neurological disorders, cognitive disorders and memory deficits, as well as acute and chronic pain.
    Type: Application
    Filed: October 21, 2016
    Publication date: November 8, 2018
    Applicant: Hua Medicine (Shanghai) Ltd.
    Inventors: Li Chen, Yuejiao Duan, Jin She, Chengde Wu
  • Publication number: 20180305346
    Abstract: One aspect of the invention relates to a series of new PCSK9 inhibitor compounds comprising piperidine ring structures, including compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another aspect of the invention relates to methods of treating PCSK9 receptor related diseases comprising administration of one or more compounds of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 20, 2018
    Publication date: October 25, 2018
    Inventors: Chengde Wu, Jie Yan, Wenjie Xu, Tao Yu, Ning Li, Shuhui Chen
  • Publication number: 20180099976
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Application
    Filed: December 11, 2017
    Publication date: April 12, 2018
    Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
  • Patent number: 9879021
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: January 30, 2018
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Mui Cheung, Michael P. Demartino, Hilary Schenck Eidam, Huiping Amy Guan, Donghui Qin, Chengde Wu, Zhen Gong, Haiying Yang, Haiyu Yu, Zhiliu Zhang
  • Patent number: 9868737
    Abstract: The present invention relates to novel pyridino[1,2-?]pyrimidone compounds represented by formula (I) or pharmaceutically acceptable salts thereof; and a method of use thereof for treating tumors.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 16, 2018
    Assignee: CISEN PHARMACEUTICAL CO., LTD.
    Inventors: Huiping Guan, Chengde Wu, Tao Yu, Lei Huang, Dongling Hao, Bo Gao, Jikui Sun, Nengyang Shi, Shuhui Chen
  • Patent number: 9856256
    Abstract: The present invention relates to novel pyridino[1,2-?]pyrimidone compounds represented by formula (I) or pharmaceutically acceptable salts thereof; and a method of use thereof for treating tumors, such as colon cancer and gastric cancer.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: January 2, 2018
    Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Chengde Wu, Tao Yu, Shuhui Chen
  • Patent number: 9809604
    Abstract: The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: November 7, 2017
    Assignees: Qingdao Huanghai Pharmaceutical Co., Ltd., Medshine Discovery Inc.
    Inventors: Chengde Wu, Zhiliu Zhang, Tao Yu
  • Publication number: 20170313683
    Abstract: Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).
    Type: Application
    Filed: July 14, 2017
    Publication date: November 2, 2017
    Inventors: Xuehai Wang, Chengde Wu, Yong Xu, Chunli Shen, Li'e Li, Guoping Hu, Yang Yue, Jian Li, Diliang Guo, Nengyang Shi, Lu Huang, Shuhui Chen, Ronghua Tu, Zhongwen Yang, Xuwen Zhang, Qiang Xiao, Hua Tian, Yanping Yu, Hailiang Chen, Wenjie Sun, Zhenyu He, Jie Shen, Jing Yang, Jing Tang, Wen Zhou, Jing Yu, Yi Zhang, Quan Liu
  • Publication number: 20170298074
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Application
    Filed: September 10, 2015
    Publication date: October 19, 2017
    Inventors: Mui CHEUNG, Michael P. DEMARTINO, Hilary Schenck EIDAM, Huiping Amy GUAN, Donghui QIN, Chengde WU, Zhen GONG, Haiying YANG, Haiyu YU, Zhiliu ZHANG
  • Publication number: 20170137420
    Abstract: Disclosed is a pyridino[1,2-a]pyrimidone analogue used as a PI3K inhibitor. The present invention particularly relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 16, 2015
    Publication date: May 18, 2017
    Inventors: Chengde WU, Tao YU, Shuhui CHEN
  • Publication number: 20170129888
    Abstract: Disclosed is a pyridino[1,2-a]pyrimidone analogue used as an mTOR/PI3K inhibitor. The present invention particularly relates to a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 16, 2015
    Publication date: May 11, 2017
    Inventors: Huiping GUAN, Chengde WU, Tao YU, Lei HUANG, Dongling HAO, Bo GAO, Jikui SUN, Nengyang SHI, Shuhui CHEN
  • Publication number: 20160272651
    Abstract: The present invention discloses a novel DGAT1 inhibitor, especially the compound of formula (I) or a pharmaceutically acceptable salt thereof, preparation and pharmaceutical composition thereof, as well as their uses in the preparation of a medicament for the prevention and treatment of Familial hyperchylomicronemia (FCS), obesity, hyperlipoproteinemia or hypertriglyceridemia.
    Type: Application
    Filed: August 18, 2014
    Publication date: September 22, 2016
    Inventors: Chengde Wu, Zhiliu Zhang, Tao Yu
  • Publication number: 20150183802
    Abstract: The invention relates to derivatives of formula (I), wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of pain.
    Type: Application
    Filed: December 22, 2014
    Publication date: July 2, 2015
    Applicant: NOVARTIS AG
    Inventors: Shuhui CHEN, Haiyang HE, Bharat LAGU, Hua QIN, Chengde WU, Yisong XIAO
  • Patent number: 9035063
    Abstract: This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung c
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: May 19, 2015
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Hilary Schenck Eidam, Huiping Amy Guan, Chengde Wu, Mui Cheung